{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:33:14Z","timestamp":1792459994115,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.005","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T14:05:35Z","timestamp":1269957935000},"page":"156-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Rituximab in Chronic Lymphocytic Leukemia"],"prefix":"10.1053","volume":"47","author":[{"given":"Samantha M.","family":"Jaglowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.005_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib3","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib4","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib5","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib6","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib8","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"2000","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib9","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1172\/JCI119869","article-title":"B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues","volume":"100","author":"Frank","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib10","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-2-29","article-title":"Update in the management of chronic lymphocytic leukemia","volume":"2","author":"Maddocks","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib14","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib21","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib22","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib24","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02780529","article-title":"Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients","volume":"17","author":"Ladetto","year":"2000","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study","volume":"69","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","article-title":"Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells","volume":"63","author":"Kay","year":"1984","journal-title":"Blood"},{"issue":"Suppl 12","key":"10.1053\/j.seminhematol.2010.01.005_bib34","first-page":"86","article-title":"High-dose rituximab therapy in chronic lymphocytic leukemia","volume":"27","author":"Keating","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib35","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib36","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib37","first-page":"36","article-title":"Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab","volume":"63","author":"Byrd","year":"2003","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/leu.2008.385","article-title":"A phase I\/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"23","author":"Woyach","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib39","first-page":"177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib40","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib41","first-page":"3642","article-title":"Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL) [abstract]","volume":"98","author":"Thomas","year":"2001","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2010.01.005_bib42","first-page":"S1","article-title":"Mechanism of action of rituximab","volume":"12","author":"Maloney","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib43","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib44","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib45","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.4049\/jimmunol.179.6.4263","article-title":"Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models","volume":"179","author":"Li","year":"2007","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib46","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","article-title":"Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia","volume":"177","author":"Williams","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib47","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib48","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","article-title":"Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib49","first-page":"1610","article-title":"Loss of CD20 Expression and exhaustion of effector cells limit ADCC in CLL patients treated with rituximab [abstract]","volume":"114","author":"Vire","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib50","article-title":"Fractionated subcutaneous Rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia","author":"Aue","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib51","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2007-07-099531","article-title":"IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro","volume":"111","author":"Gowda","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910450213","article-title":"Deficient production of tumor necrosis factor by peripheral-blood monocytes in chronic lymphocytic leukemia","volume":"45","author":"Flieger","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib53","doi-asserted-by":"crossref","first-page":"e5500","DOI":"10.1371\/journal.pone.0005500","article-title":"Functional analysis of a dominant negative mutation of interferon regulatory factor 5","volume":"4","author":"Yang","year":"2009","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib54","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib55","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib56","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib57","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib58","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","article-title":"Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance","volume":"21","author":"Bannerji","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.325.4.2","article-title":"Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate","volume":"4","author":"Arditti","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib60","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","article-title":"Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells","volume":"83","author":"Stanglmaier","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib62","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib63","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib64","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib65","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib68","first-page":"539","article-title":"Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712 [abstract]","volume":"114","author":"Woyach","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib69","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.21535","article-title":"The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia","volume":"104","author":"Del Poeta","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib70","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib72","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib74","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood-2008-10-184853","article-title":"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens","volume":"113","author":"Lin","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib75","first-page":"325","volume":"112","author":"Hallek","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib76","first-page":"lba-1","article-title":"Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial [abstract]","volume":"112","author":"Robak","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib77","first-page":"781","article-title":"Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial [abstract]","volume":"112","author":"Stilgenbauer","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib78","first-page":"535","volume":"114","author":"Hallek","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib79","first-page":"538","volume":"114","author":"Lepretre","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib80","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","article-title":"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses","volume":"27","author":"Lamanna","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib82","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib83","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib84","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib85","first-page":"327","article-title":"Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia [abstract]","volume":"112","author":"Reynolds","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib86","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib87","first-page":"405","volume":"114","author":"Rummel","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib88","first-page":"205","article-title":"Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]","volume":"114","author":"Fischer","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib89","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.31.31","article-title":"Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract]","volume":"108","author":"Wierda","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib90","first-page":"2095","article-title":"CFAR, an active frontline regimen for high-risk patients with CLL, including those with del 17p [abstract]","volume":"112","author":"Wierda","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib91","first-page":"208","article-title":"Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia [abstract]","volume":"114","author":"Parikh","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib92","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2007-03-082024","article-title":"Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines","volume":"111","author":"Pathan","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib93","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib94","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd JC","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428199909083393","article-title":"High dose methyl prednisolone in refractory chronic lymphocytic leukaemia","volume":"34","author":"Thornton","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib96","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib97","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/leu.2008.214","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia","volume":"22","author":"Castro","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib98","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib99","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1080\/10428190701724801","article-title":"Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features","volume":"48","author":"Bowen","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib102","first-page":"210","volume":"114","author":"Lin","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib104","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib106","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1200\/jco.2009.27.15_suppl.7031","article-title":"Phase I\/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) [abstract]","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","author":"Dearden","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib108","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib109","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.V99.3.1092","article-title":"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia","volume":"99","author":"Ghazal","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.20671","article-title":"The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia","volume":"81","author":"Pamuk","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2257.2006.00738.x","article-title":"Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab","volume":"28","author":"Swords","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib112","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-007-0651-0","article-title":"Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient","volume":"62","author":"Gentile","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib113","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib114","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D'Arena","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib116","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib117","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2403914","article-title":"Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy","volume":"19","author":"Niscola","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib118","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib119","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/sj.leu.2402567","article-title":"Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge","volume":"16","author":"Skrabs","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib121","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","article-title":"Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy","volume":"102","author":"Westhoff","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib122","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib123","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1080\/10428190600612586","article-title":"Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature","volume":"47","author":"Mian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib124","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10072-008-0857-x","article-title":"Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab","volume":"29","author":"Bonavita","year":"2008","journal-title":"Neurol Sci"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00277-007-0411-6","article-title":"Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature","volume":"87","author":"Pelosini","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-008-0168-2","article-title":"Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature","volume":"88","author":"Yokoyama","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib129","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/qjmed\/hcn085","article-title":"Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL","volume":"101","author":"Klepfish","year":"2008","journal-title":"Q J Med"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib131","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1749-6632.2009.04803.x","article-title":"Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement\/rituximab interactions & clinical results in refractory CLL","volume":"1173","author":"Klepfish","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib132","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.005_bib133","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:43Z","timestamp":1758522043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0037196310000065"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}